Utama › Melanoma › Nebraska › Omaha
Kajian klinikal Melanoma di Omaha, NE
12 kajian untuk Melanoma sedang mencari peserta di lokasi dalam dan sekitar Omaha (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Mengambil pesertaFasa 2
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- Nebraska Medicine-Bellevue, Bellevue · 9 mi jauh
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Mengambil pesertaFasa 3
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
Mengambil pesertaFasa 3
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
Project: Every Child for Younger Patients With Cancer
Mengambil pesertaKajian pemerhatian
- Children's Hospital and Medical Center of Omaha, Omaha
- University of Nebraska Medical Center, Omaha
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Mengambil pesertaFasa 1/2
- Nebraska Cancer Specialists, Omaha
Integrated Cancer Repository for Cancer Research
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Methodist Estabrook Cancer Center, Omaha
- Nebraska Methodist Health System, Omaha
- University of Nebraska Medical Center, Omaha
- dan 1 lagi
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
Mengambil pesertaFasa 1/2
- Nebraska Cancer Specialists, Omaha
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Mengambil pesertaFasa 3
- TIERING Percentiles, Omaha
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Omaha
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Mengambil pesertaFasa 1/2
- University of Nebraska Medical Center, Omaha
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Mengambil peserta
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medicine, Omaha
- Nebraska Medicine - Bellevue, Bellevue · 9 mi jauh
Kajian Melanoma di bandar lain
- Houston, TX59 kajian
- New York City, NY38 kajian
- Los Angeles, CA34 kajian
- Nashville, TN33 kajian
- Pittsburgh, PA31 kajian
- Boston, MA26 kajian
- Philadelphia, PA23 kajian
- San Francisco, CA22 kajian
- Durham, NC21 kajian
- Atlanta, GA21 kajian
- St. Louis, MO21 kajian
- Salt Lake City, UT21 kajian
Kajian lain di Omaha
- Kanser Prostat27 kajian
- Kanser Paru-paru Bukan Sel Kecil24 kajian
- Kanser Payudara22 kajian
- Kanser Kolorektal18 kajian
- Kanser (semua jenis)18 kajian
- Mieloma Pelbagai16 kajian
- Limfoma Bukan Hodgkin14 kajian
- Kanser Ovari14 kajian
- Kanser Pankreas14 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher13 kajian
- Kegagalan Jantung13 kajian
- Kanser Metastatik13 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.